TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ACETYLCYSTEINE

ACETYLCYSTEINE Reduction Activity
Gastroenterology Approved 1992-04-30
20
Indications
--
Phase 3 Trials
33
Years on Market

Details

Status
Prescription
First Approved
1992-04-30
Routes
INHALATION, ORAL, INTRAVENOUS, Inhalation, Oral
Dosage Forms
SOLUTION, INJECTABLE, Solution

ACETYLCYSTEINE Approval History

Loading approval history...

What ACETYLCYSTEINE Treats

2 indications

ACETYLCYSTEINE is approved for 2 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Acetaminophen Overdose
  • Hepatic Injury
Source: FDA Label

Drugs Similar to ACETYLCYSTEINE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ACETYLCYSTEINE FDA Label Details

Pro

Indications & Usage

Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with an acute ingestion or from repeated supratherapeutic ingestion (RSI) .

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.